Cambridge Investment Research Advisors, Inc. Altimmune, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Altimmune, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 12,121 shares of ALT stock, worth $94,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,121Holding current value
$94,058% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ALT
# of Institutions
186Shares Held
39.3MCall Options Held
913KPut Options Held
743K-
Black Rock Inc. New York, NY5.32MShares$41.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.98MShares$38.7 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.88MShares$30.1 Million0.01% of portfolio
-
State Street Corp Boston, MA3.41MShares$26.5 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.75MShares$21.3 Million1.44% of portfolio
About Altimmune, Inc.
- Ticker ALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,025,300
- Market Cap $380M
- Description
- Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...